IACH 2021 | Current challenges faced with CAR T-cell therapies
Christian Chabannon, MD, PhD, Institut Paoli Calmettes, Marseille, France, talks on the financial and sociological challenges associated with the use of chimeric antigen receptor (CAR)-T cell therapies for the treatment of hematological malignancies. The cost of CAR T-cell therapies including treatment, hospital re-organization, inpatient stay and patient follow-up is currently extremely high. Prof. Chabannon describes how debates between companies and healthcare authorities are crucial to meeting current healthcare priorities and reducing costs. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.
Disclosures
Christian Chabannon, MD, PhD, has participated in consultancy work or speakers bureaus for Kite/Gilead, Novartis, BMS/Celgene, Janssen, Bellicum Pharmaceuticals, BlueBirdBio, Sanofi SA and Terumo BCT.
